In conclusion, our study suggested that MD2 deficiency or inhibition by L6H21 can mitigate Ang II-induced liver dysfunction, pathological injury, inflammation and fibrosis, and activation of NF-κB and ERK pathways through reducing the formation of the MD2/TLR4 complex. The gene discussed is NFKB1; the disease is Decreased liver function.